Cullinan Therapeutics (CGEM) Tax Provisions (2022 - 2023)
Cullinan Therapeutics' (CGEM) quarterly Tax Provisions came in at $14.1 million in Q4 2023, up 842.11% year-on-year from $1.5 million in Q4 2022, and up 842.11% quarter-over-quarter from -$1.9 million in Q4 2022.
Cullinan Therapeutics (CGEM) Tax Provisions (2022 - 2023) Analysis & Trends
Cullinan Therapeutics' Tax Provisions history runs 2 years deep, the most recent figure standing at $14.1 million for Q4 2023.
- On a quarterly basis, Tax Provisions rose 842.11% year-over-year to $14.1 million in Q4 2023; TTM through Dec 2023 was $14.1 million, a 66.49% decrease from a year earlier, with the FY2024 full-year figure at -$35.3 million, down 350.45% from the prior year.
- Tax Provisions improved to $14.1 million in Q4 2023 per CGEM's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Tax Provisions topped out at $66.1 million in Q2 2022 and bottomed at -$19.6 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 31.86 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 179.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 14.10 Mn |
| Dec 31, 2022 | -1.90 Mn |
| Sep 30, 2022 | -2.52 Mn |
| Jun 30, 2022 | 66.07 Mn |
| Mar 31, 2022 | -19.57 Mn |